<p>RNA splicing is at the forefront of providing insights into diseases that are linked back to RNA errors. Dr. Maria Luisa Pineda, CEO & Co-Founder at Envisagenics, explains how AI, HPC (high-performance computing), and genetic data can provide the insights needed for targeted drug discovery in oncology and other genetic conditions faster and more accurately than ever. </p>

RNA splicing is at the forefront of providing insights into diseases that are linked back to RNA errors. Dr. Maria Luisa Pineda, CEO & Co-Founder at Envisagenics, explains how AI, HPC (high-performance computing), and genetic data can provide the insights needed for targeted drug discovery in oncology and other genetic conditions faster and more accurately than ever.

<p>RNA splicing is at the forefront of providing insights into diseases that are linked back to RNA errors. Dr. Maria Luisa Pineda, CEO &amp; Co-Founder at Envisagenics, explains how AI, HPC (high-performance computing), and genetic data can provide the insights needed for targeted drug discovery in oncology and other genetic conditions faster and more accurately than ever.&nbsp;</p>

AI: The New Pipeline for Targeted Drug Discovery

IEEE SA Voice shares insights and perspectives from the IEEE SA community, subject matter experts, and industry leaders that are working to raise the world's standards, drive market solutions, and much more, keeping you at the forefront of technological innovation for the benefit of humanity.

Share AI: The New Pipeline for Targeted Drug Discovery

Sign up to save your podcasts

AI: The New Pipeline for Targeted Drug Discovery

AI: The New Pipeline for Targeted Drug Discovery